Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 5 | 2019 | 270 | 1.340 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2018 | 12 | 1.120 |
Why?
|
| Sarcoma | 1 | 2019 | 28 | 0.630 |
Why?
|
| Urinary Incontinence | 1 | 2018 | 20 | 0.600 |
Why?
|
| Spinal Dysraphism | 1 | 2018 | 14 | 0.590 |
Why?
|
| Tomography, Optical | 4 | 2011 | 22 | 0.560 |
Why?
|
| Venereal Tumors, Veterinary | 3 | 2011 | 6 | 0.560 |
Why?
|
| Urinary Tract Infections | 2 | 2014 | 39 | 0.540 |
Why?
|
| Transitional Care | 1 | 2016 | 3 | 0.540 |
Why?
|
| Transition to Adult Care | 1 | 2015 | 8 | 0.510 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2015 | 3 | 0.490 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 15 | 0.490 |
Why?
|
| Prostate | 3 | 2011 | 51 | 0.480 |
Why?
|
| Chronic Disease | 1 | 2015 | 264 | 0.460 |
Why?
|
| Quality of Life | 1 | 2018 | 463 | 0.450 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 100 | 0.450 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2013 | 5 | 0.450 |
Why?
|
| Abscess | 1 | 2013 | 24 | 0.440 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 44 | 0.440 |
Why?
|
| Kidney Diseases | 1 | 2013 | 58 | 0.430 |
Why?
|
| Hematuria | 1 | 2013 | 10 | 0.430 |
Why?
|
| Fracture Fixation, Internal | 1 | 2013 | 32 | 0.420 |
Why?
|
| Urethra | 1 | 2013 | 33 | 0.420 |
Why?
|
| Bone Screws | 1 | 2013 | 43 | 0.410 |
Why?
|
| Sarcoma, Ewing | 1 | 2011 | 14 | 0.370 |
Why?
|
| Hypoxia | 1 | 2011 | 85 | 0.360 |
Why?
|
| Male | 17 | 2019 | 12866 | 0.350 |
Why?
|
| Cystitis, Interstitial | 2 | 2007 | 17 | 0.300 |
Why?
|
| Humans | 18 | 2019 | 26856 | 0.290 |
Why?
|
| Young Adult | 3 | 2018 | 2584 | 0.240 |
Why?
|
| Adult | 8 | 2018 | 7389 | 0.230 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2014 | 4 | 0.220 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 917 | 0.210 |
Why?
|
| Urinary Bladder | 1 | 2004 | 117 | 0.210 |
Why?
|
| Ultrasonography | 5 | 2011 | 228 | 0.210 |
Why?
|
| Spinal Cord Injuries | 2 | 2014 | 55 | 0.210 |
Why?
|
| Child | 4 | 2017 | 2152 | 0.200 |
Why?
|
| Adolescent | 4 | 2017 | 2960 | 0.190 |
Why?
|
| Algorithms | 2 | 2016 | 419 | 0.180 |
Why?
|
| Postoperative Complications | 3 | 2017 | 605 | 0.170 |
Why?
|
| Middle Aged | 5 | 2018 | 6825 | 0.170 |
Why?
|
| Dogs | 4 | 2011 | 504 | 0.150 |
Why?
|
| Cecostomy | 1 | 2017 | 4 | 0.140 |
Why?
|
| Fecal Incontinence | 1 | 2017 | 16 | 0.140 |
Why?
|
| Female | 8 | 2018 | 14462 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 52 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2016 | 6 | 0.140 |
Why?
|
| Fournier Gangrene | 1 | 2016 | 4 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2017 | 2267 | 0.130 |
Why?
|
| Urothelium | 2 | 2007 | 35 | 0.130 |
Why?
|
| Emotions | 1 | 2017 | 131 | 0.130 |
Why?
|
| Caregivers | 1 | 2017 | 110 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2016 | 162 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2018 | 860 | 0.120 |
Why?
|
| Length of Stay | 1 | 2016 | 218 | 0.120 |
Why?
|
| Vincristine | 1 | 2015 | 9 | 0.120 |
Why?
|
| Etoposide | 1 | 2015 | 19 | 0.120 |
Why?
|
| Bleomycin | 1 | 2015 | 11 | 0.120 |
Why?
|
| Phenotype | 2 | 2014 | 664 | 0.120 |
Why?
|
| Prostatectomy | 1 | 2015 | 83 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 225 | 0.120 |
Why?
|
| Infant | 2 | 2016 | 963 | 0.120 |
Why?
|
| Urolithiasis | 1 | 2014 | 1 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 915 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2016 | 1090 | 0.120 |
Why?
|
| Ureteroscopy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 43 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 151 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 22 | 0.110 |
Why?
|
| Cisplatin | 1 | 2015 | 172 | 0.110 |
Why?
|
| Recurrence | 1 | 2015 | 316 | 0.110 |
Why?
|
| Chromosomes, Human, X | 1 | 2014 | 35 | 0.110 |
Why?
|
| Urinary Tract | 1 | 2013 | 3 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 2013 | 6 | 0.110 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 465 | 0.110 |
Why?
|
| Drainage | 1 | 2013 | 42 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 77 | 0.110 |
Why?
|
| Urinary Catheterization | 1 | 2013 | 15 | 0.110 |
Why?
|
| Pelvic Bones | 1 | 2013 | 14 | 0.110 |
Why?
|
| Device Removal | 1 | 2013 | 30 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 377 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2016 | 848 | 0.100 |
Why?
|
| Kidney Calculi | 1 | 2012 | 6 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2013 | 44 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 6 | 0.100 |
Why?
|
| Rectum | 2 | 2010 | 50 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 14 | 0.100 |
Why?
|
| Infrared Rays | 2 | 2009 | 23 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2011 | 59 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 49 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 367 | 0.100 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2011 | 72 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2011 | 221 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 160 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2010 | 116 | 0.080 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2009 | 4 | 0.080 |
Why?
|
| Dog Diseases | 1 | 2009 | 28 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 496 | 0.080 |
Why?
|
| Keratins, Type I | 1 | 2007 | 1 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2007 | 37 | 0.070 |
Why?
|
| Replantation | 1 | 2007 | 7 | 0.070 |
Why?
|
| Ureter | 1 | 2007 | 7 | 0.070 |
Why?
|
| Hydronephrosis | 1 | 2007 | 11 | 0.070 |
Why?
|
| Radioisotope Renography | 1 | 2007 | 29 | 0.070 |
Why?
|
| Aged | 4 | 2016 | 5169 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2005 | 24 | 0.060 |
Why?
|
| Animals | 4 | 2011 | 9954 | 0.060 |
Why?
|
| Biomarkers | 2 | 2007 | 731 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2007 | 466 | 0.060 |
Why?
|
| Uroplakin II | 1 | 2004 | 4 | 0.060 |
Why?
|
| Cadherins | 1 | 2004 | 24 | 0.060 |
Why?
|
| Chondroitin Sulfates | 1 | 2004 | 23 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2017 | 2444 | 0.050 |
Why?
|
| Mice | 1 | 2011 | 4402 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 981 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 316 | 0.050 |
Why?
|
| Neurogenic Bowel | 1 | 2017 | 4 | 0.040 |
Why?
|
| Appendix | 1 | 2017 | 9 | 0.040 |
Why?
|
| Constipation | 1 | 2017 | 21 | 0.040 |
Why?
|
| Catheterization | 1 | 2017 | 50 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 61 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2017 | 143 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 716 | 0.030 |
Why?
|
| Urinary Bladder Calculi | 1 | 2014 | 1 | 0.030 |
Why?
|
| Lithotripsy | 1 | 2014 | 7 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 13 | 0.030 |
Why?
|
| Melanins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 14 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 72 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 758 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2014 | 47 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 453 | 0.030 |
Why?
|
| Radiography | 1 | 2012 | 200 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 1927 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 98 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 290 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 664 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 457 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 368 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
|
| Pelvis | 1 | 2009 | 37 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 88 | 0.020 |
Why?
|
| Calibration | 1 | 2008 | 28 | 0.020 |
Why?
|
| Chickens | 1 | 2008 | 59 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 450 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2008 | 96 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2007 | 17 | 0.020 |
Why?
|
| Ureterocele | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 114 | 0.020 |
Why?
|
| Ureteral Obstruction | 1 | 2007 | 12 | 0.020 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2007 | 11 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2007 | 54 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2007 | 115 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 701 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2005 | 18 | 0.020 |
Why?
|
| Gene Library | 1 | 2005 | 45 | 0.020 |
Why?
|
| Health | 1 | 2005 | 12 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 76 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 1259 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1394 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 399 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 645 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 443 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 2017 | 0.010 |
Why?
|